May 1, 2008 - Monogram Biosciences, Inc. (Nasdaq: MGRM) announced that the company's HER1 and HER3 Quantitative Protein Assays are now available for clinical development use. Built on Monogram's VeraTag™ platform, the HER1 and HER3 assays provide unique, quantitative measurements of protein expression and activity in formalin fixed paraffin embedded (FFPE) tumor samples. These assays supplement HERmark™, Monogram's HER2 and HER2:HER2 Homodimer Breast Cancer Assay, and expands the potential clinical reach of Monogram's VeraTag assays to lung, colorectal and other cancers... Monogram Biosciences' Press Release -
May 8, 2008
Monogram Biosciences : HER1 and HER3 VeraTag™ Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
May 1, 2008 - Monogram Biosciences, Inc. (Nasdaq: MGRM) announced that the company's HER1 and HER3 Quantitative Protein Assays are now available for clinical development use. Built on Monogram's VeraTag™ platform, the HER1 and HER3 assays provide unique, quantitative measurements of protein expression and activity in formalin fixed paraffin embedded (FFPE) tumor samples. These assays supplement HERmark™, Monogram's HER2 and HER2:HER2 Homodimer Breast Cancer Assay, and expands the potential clinical reach of Monogram's VeraTag assays to lung, colorectal and other cancers... Monogram Biosciences' Press Release -
